The dual agonism enhances both weight reduction and metabolic insulin response
Integrin 1 has the biological function of a hub integrin and acts as a receptor for specific ECM components, revealed in kidney epithelial cells (Glynne et al., 2001) or in T cell lymphoma (Sato et al., 2005)
While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
In healthy, non-hypertensive women, this is clinically acceptable
